key: cord-0982665-qhdbfck9
authors: Prapty, Chowdhury Nusaiba Binte Sayed; Rahmat, Raad; Araf, Yusha; Shounak, Samiha Kamal; Noor‐A‐Afrin,; Rahaman, Tanjim Ishraq; Hosen, Mohammad Jakir; Zheng, Chunfu; Hossain, Md. Golzar
title: SARS‐CoV‐2 and dengue virus co‐infection: Epidemiology, pathogenesis, diagnosis, treatment, and management
date: 2022-03-03
journal: Rev Med Virol
DOI: 10.1002/rmv.2340
sha: 5a989e12e6fc796dd80578b68b2b862c0eee4881
doc_id: 982665
cord_uid: qhdbfck9

SARS‐CoV‐2 and dengue virus co‐infection cases have been on the rise in dengue‐endemic regions as coronavirus disease 2019 (COVID‐19) spreads over the world, posing a threat of a co‐epidemic. The risk of comorbidity in co‐infection cases is greater than that of a single viral infection, which is a cause of concern. Although the pathophysiologies of the two infections are different, the viruses have comparable effects within the body, resulting in identical clinical symptoms in the case of co‐infection, which adds to the complexity. Overlapping symptoms and laboratory features make proper differentiation of the infections important. However, specific biomarkers provide precise results that can be utilised to diagnose and treat a co‐infection, whether it is simply COVID‐19, dengue, or a co‐infection. Though their treatment is distinguished, it becomes more complicated in circumstances of co‐infection. As a result, regardless of whatever infection the first symptom points to, confirmation diagnosis of both COVID‐19 and dengue should be mandatory, particularly in dengue‐endemic regions, to prevent health deterioration in individuals treated for a single infection. There is still a scarcity of concise literature on the epidemiology, pathophysiology, diagnosis, therapy, and management of SARS‐CoV‐2 and dengue virus co‐infection. The epidemiology of SARS‐CoV‐2 and dengue virus co‐infection, the mechanism of pathogenesis, and the potential impact on patients are summarised in this review. The possible diagnosis with biomarkers, treatment, and management of the SARS‐CoV‐2 and dengue viruses are also discussed. This review will shed light on the appropriate diagnosis, treatment, and management of the patients suffering from SARS‐CoV‐2 and dengue virus co‐infection.

Agricultural University, Mymensingh, Bangladesh. Email: mghossain@bau.edu.bd management of the patients suffering from SARS-CoV-2 and dengue virus coinfection.

biomarkers, co-infection, dengue virus, epidemiology, management, mechanism, SARS-CoV-2

There was an influx of patients with pneumonia of unknown origin in Wuhan, Hubei Province, China, in December 2019. 1, 2 Sequencing the viral genome isolated from the pneumonia patients revealed that the etiological agent was the novel beta coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belonging to the Coronaviridae family, becoming the 7th member of the family to cause disease in humans. 1 The coronavirus disease 2019 caused by SARS-CoV-2 showed symptoms that resembled previous outbreaks of two other beta coronaviruses, Middle East respiratory syndrome coronavirus and SARS-CoV. The COVID-19 patients typically exhibit symptoms such as mild pneumonia, including fever, cough, and chest pains; however, the symptoms could become moderate to severe with the patients manifesting dyspnoea, elevated respiratory frequency, reduced blood oxygen saturation, and lung infiltration. Respiratory failure, septic shock, and multiple organ failure could be critical or fatal in some circumstances. 3 However, having human-to-human transmission capabilities, the virus soon spread globally, compelling World Health Organization (WHO) to declare it a 'Public Health Emergency' on 30 January 2020, and eventually labelled the outbreak a 'pandemic' on 11 March 2020. 2, 4 As of 14 November 2021, 252,920,587 confirmed COVID-19 cases were reported in 224 countries with 5,095,436 confirmed fatalities. 4 Dengue caused by the dengue viruses (DENV) is one of the major threats among vector-borne diseases in tropical and subtropical regions, infested with its vectors, Aedes aegypti and Aedes albopictus. 5, 6 It is caused by four serotypes of the virus, DENV-1, DENV-2, DENV-3, and DENV-4, belonging to the Flaviviridae family. 5 Dengue might induce nonspecific febrile illness dengue fever when an infected mosquito bites a person. 5 In some circumstances, however, the disease could become more serious, even fatal in some instances, if it leads to dengue haemorrhagic fever and dengue shock syndrome involving plasma leakage coagulopathy, circulatory shock, and multiorgan failure. 5 According to WHO, there has been an alarming 8fold increase in dengue infection during the last 2 decades. The incidence is estimated to be 100-400 million infections annually, while in 2015, it caused 4032 deaths. 7 Dengue is usually endemic or hyperendemic (circulation of multiple serotypes of DENVs) in countries that are relatively compromised in terms of health care systems. As a result, with the already existing pressure due to the COVID-19 pandemic, the increasing incidence of dengue during the monsoon season posed a serious threat due to the existence of simultaneous outbreaks of these diseases, which might be torrential for the health care system in these countries, especially in cases involving co-infection by SARS-CoV-2 and DENV. 7 Thirty-one such co-infection cases have been observed across multiple case studies in South American, South African, and South Asian regions. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Despite differences in the pathophysiology, infections with the viruses simultaneously share several clinical symptoms and laboratory characteristics. 4 These overlapping symptoms render it harder to diagnose the infection, leading to misdiagnosis and missing out on co-infection cases. For example, some common symptoms of both infections include fever, headache, nausea. 4 The impact of co-infection, specifically in the dengue-endemic regions, can lead to the rise of a co-epidemic, possibly overburdening a nation's healthcare system. Therefore, along with the appropriate preventive measures, special care of patients coinfected with SARS-CoV-2 and DENV in the context of diagnosis, treatment, and management should be taken based on the previous histories and COVID-19 and dengue-endemic prone regions. Therefore, this review focussed on the epidemiology, pathogenesis, diagnosis, treatment, and management of patients coinfected with SARS-CoV-2 and DENV.

The COVID-19 pandemic surmounted substantial pressure on the countries' healthcare systems with the existing pressure from dengue in endemic and hyperendemic (co-occurrence of multiple serotypes of DENVs) regions, especially with cases of COVID-19 and dengue co-infection. 7 The Centres for Disease Control and Prevention (Centres for Disease Control and Prevention) reported a total of 13 patients who had COVID-19 and dengue co-infection in Buenos Aires, Argentina, during a study from March to June 2020. Among them, 6 were female, 7 were males, and the median age was 37 (29-50 years) . None of the patients were shown to have severe dengue, while only one patient had severe COVID-19, and all the patients were survived. 8 A study involving patients from tertiary care hospitals in Singapore was carried out where nine patients were initially suspected of having been coinfected with DENV and SARS-CoV-2.

However, eight cases were later diagnosed as COVID-19 patients with false-positive dengue IgM. The ninth patient, a 31-year-old Bangladeshi male, tested positive for dengue nonstructural protein-1 (NSP1) and positive SARS-CoV-2 polymerase chain reaction (PCR) but negative for IgM. Dengue, therefore, was diagnosed as COVID-19 and probable dengue coinfected patient. The patient fully recovered without complication. 10 Another study in Pakistan reported five patients who tested positive for COVID-19 and dengue (DENV2) following real-time reverse transcription PCR (rRT-PCR).

The median age of the patients was 43 years (43.4 � 17.98), among whom three were males and two were females. In this study, three of the patients passed away, while the remaining two were hospitalised during the study. 11 Additionally, eight different case studies involving nine patients were reported in Thailand, the Philippines, Africa, Reunion Island, India, the Maldives, and Brazil. In this study, a 50-year-old female flight attendant, 62-year-old female, 18-and 44-year-old males, a 9month-old infant, 22-year-old pregnant female, 38-and 39-year-old Asian males, and a 56-year-old woman. All the patients, except the 9month-old female child, had mild to moderate severity, while the latter exhibited moderate to severe symptoms. All the patients in these case report made a full recovery. 12 Ocean, among whom five passed away (Figures 1 and 2 ). [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Considering the glaring death rate of SARS-CoV-2 and DENV coinfection of 16.13% (5 deaths among 31 coinfected patients), significantly higher than the global death rates of single infection of both diseases. The COVID-19 has a death rate of around 2.04%, which varies between 0.8% and 2.5%. The SARS-CoV-2 and DENV coinfection in these regions will perhaps continue to burden the healthcare system substantially. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 

The SARS-CoV-2 and DENV consist of a single-stranded, positivesense RNA genome. 21 However, SARS-CoV-2 contains spike glycoprotein, which interacts with the host cellular receptor angiotensinconverting enzyme-2 (ACE2) to enter the cells. 21, 22 In contrast, DENV enters into the cells through various groups of attachment factors, including C-type lectins DC-SIGN (CD209), mannose receptor (CD206), glycosaminoglycans (heparan sulphate), and immunomodulatory proteins (TIM/TAM receptors). 20,23,24 SARS-CoV-2 infection and interaction with ACE2 stimulate an inflammatory immune response, a cytokine storm, during the COVID-19 infection. 25, 26 Such cytokine storms are also observed in dengue infections and elicited by increasing antibody concentrations. 27 Plasma leakage, including other vascular disorders and permeability, and disseminated intravascular coagulation that have been observed in COVID-19 and dengue co-infection is linked to several immune-mediators, including proinflammatory cytokines, tumour necrosis factor, IL-6, and interferon (IFN)-γ, as well as chemokines, such as migration inhibitory factor. [28] [29] [30] The COVID-19 and dengue exhibit similar pathophysiology for capillary leakage, thrombocytopaenia, and coagulopathy during co-infection. 31 In dengue, plasma leakage is linked to the interaction of NSP1-specific antibodies with endothelial cell surface proteins, leading to increased viral multiplication and inflammatory cytokine release. 9 Endothelial cells are activated, and platelets are targeted by NSP1 antibodies, which are highly immunogenic and stimulate the production of autoantibodies. 29 In DENV-2, anti-NSP1 antibodies inhibit platelet aggregation and cause platelet lysis associated with transient thrombocytopaenia. [32] [33] [34] While COVID-19 is distinguished by elevated inflammatory cytokine production, particularly IL-6, and over-activation of effector T-cell activity, leading to capillary leakage and thrombocytopaenia. 31 Furin protease plays a crucial role in the SARS-CoV-2 infection and viral entry into the alveolar cells. 35, 36 The SARS-CoV-2 replicates in the alveolar epithelial cells, leading to alveolar damage, oedema, hyaline membrane formation, immune cell infiltration into the lungs, and the desquamation of pneumocytes that causes Acute respiratory distress syndrome. 37 It is evident from these studies that in co-infection cases, both SARS-CoV-2 and DENV, either synergistically or individually, lead to damage to different organs, especially the lungs, liver, cardiovascular system, and the Central nervous system (CNS). As a result, COVID-19 and dengue co-infection correlate with more severe symptoms with poorer prognoses than single infections. Viruses can actively infiltrate the CNS during the SARS-CoV-2 and DENV coinfection. 42, 43 Though the entrance of DENV into the CNS is unclear, it is suggested that the disturbance mediated by cytokine during DENV infection alters neurovascular unit integrity. After that, DENV can access the CNS through the blood-brain barrier. 44 Anti-DENV IgM, viral RNA, and DENV NSP1 can be detected in the cerebrospinal fluid during infection that may account for the common neurological manifestations of dengue, such as encephalitis and encephalopathy, which are associated with the severe disease with slower recovery. [45] [46] [47] [48] Virus entrance into the cell may depend on the endosomal/lysosomal cysteine proteases cathepsin B and cysteine proteases cathepsin L even though the activity of these two enzymes is not essential to infect the cerebral nervous system, SARS-CoV-2 may also utilise the presumed complementary receptor CD147 (expressed in high levels in the brain). 26, 36 The neurological signs and symptoms during COVID-19 infection also reported headache, dizziness, acute cerebrovascular disease, epilepsy, ataxia, anosmia, and muscle pain demyelinating encephalomyelitis. 49 Thus, severe neurological complications may occur in COVID-19 and dengue coinfection cases. The possible mechanism and pathophysiology for SARS-CoV-2 and DENV co-infection have been illustratively summarized in Figure 3 .

The COVID-19 and dengue both have certain biomarkers that act as measurable parameters to indicate the process and progress of pathogenesis and the results of therapeutic interventions. Among the plethora of biomarkers, some shared by both viral infections, individually, including increased levels of certain cytokines such as TNF-⍺, IL-8, IL-6, IL-10, increased infection biomarkers such as C-reactive protein (CRP) and interferon gamma-induced protein 10 (induced protein 10), particularly in severe COVID-19 cases. 50 In the case of COVID-19, the increase in IL-6 levels are more dramatic, whereas, for dengue, it is the rise in the concentration of IL-10 that is more prominent. 51 Alternatively, the contrasting biomarkers for the two diseases include, more notably increased leucocytes and neutrophil count in COVID-19 infection compared to a decreased one in dengue, the high platelet count in COVID-19 versus low platelet count in dengue, lower Alanine transaminase (ALT) and Aspartate transaminase (AST) levels in the former and a higher than normal level in the latter, as well as a high neutrophil-to-lymphocyte ratio (NLR) in COVID-19 compared to a lower than normal levels in case of dengue. 52, 53 In co-infection of SARS-CoV-2 and the DENV, the biomarkers turned out to be a mixture from both; the level of ALT in the liver was elevated greatly along with slight increases of creatinine in the kidneys, there was thrombocytopaenia (low platelet counts), the numbers of lymphocytes and leucocytes reduced considerably too, alongside with high CRP, and reduced haemoglobin and haematocrit less commonly (Table 1 and Figures 4) . 65 

It is often very difficult to diagnose and distinguish between COVID-19 and dengue in the same patients due to sharing some common symptoms. There are several common clinical features such as fever, headache, myalgia, asthenia, nausea, arthralgia, and sometimes cough in the case of COVID-19 and dengue ( Figure 5 ). Frequent complaints of vomiting, retro-orbital pain, and skin rashes in certain cases are all more particular to dengue infection than COVID-19 ( Figure 5 ).

Moreover, in severe dengue cases, pulmonary oedema showed clinical and radiological features with severe pneumonia in COVID- 19. 64 As a result, precise and accurate diagnosis based on the clinical symptoms poses a challenge.

COVID-19 is a multisystem disease with a heterogeneous spectrum, and rRT-PCR is most commonly used to confirm the infection.

The tentative clinical diagnosis involves monitoring typical respiratory syndromes along with recent exposure ( Figure 5 ). An early tentative diagnosis can be made by a Chest Computerised Tomography (CT) scan, which has a sensitivity of 97.2%. The rRT-PCR has a sensitivity of 83.3% though it sometimes showed false negatives. Therefore, simultaneous CT scans followed by the repeating rRT-PCR are necessary in case of further confirmatory diagnosis of COVID-19. 68 On the other hand, diagnosis of dengue infection is mainly performed by IgM capture enzyme-linked immunosorbent assay (ELISA), detection of nonstructural protein-1 antigen (NSP1Ag), dengue Reverse transcription-polymerase chain reaction (RT-PCR), and sometimes virus isolation. 69 The rapid NSP1 antigen and NSP1 ELISA are commonly used as initial diagnostic tools due to their availability, sensitivity, and specificity rates of 55.5% and 92%. 70 RT-PCR is then performed to confirm unclear/mixed symptoms. 14 However, in the case of a co-infection, common laboratory tests, such as Complete blood count and ALT, can be useful and efficient.

The NLR values indicate whether leukopenia or lymphopenia is occurring to distinguish between the infections. In the case of dengue, a common diagnostic test shows progressive leukopenia followed by a rapid fall in platelet count and a rising haematocrit. In contrast, in COVID-19, leukopenia or leucocytosis can occur with lymphopenia as the more common indicator of severity. 71 For a case classified as dengue through initial clinical symptoms, a test reveals a significant increase of ALT than AST, which can indicate another infection, in some instances, which could be a SARS-CoV-2 and DENV co-infection. In almost all co-infection cases, thrombocytopaenia is a prominent and consistent condition due to lower platelet synthesis resulting from bone marrow suppression by the viruses and immune-mediated clearing of the platelets. Another hypothesis is that the platelets are destroyed by the autoantibodies and immune complexes formed due to SARS-CoV-2 and DENV infection. 72 PRAPTY ET AL. On the other hand, a potential concern remains unchanged: the coexistence of fever after receiving the COVID-19 vaccination with an endemic tropical illness. An endemic haemorrhagic fever that may induce thrombocytopaenia in a COVID-19 vaccination recipient must be identified. This clinical issue might be misdiagnosed as a vaccinerelated adverse event. 56 Mild to moderate Dengue and COVID-19 coinfected patients should be constantly monitored, ideally in a hospital, since they can quickly develop to a severe stage, and they should be referred to a higher facility if warning symptoms are recognized.

Meanwhile, all secondary and tertiary level hospitals must be ready to handle severe dengue and COVID-19 cases. Co-infection has higher morbidity and must be treated with caution and care.

Treatment should be decided based on the most severe symptoms; T A B L E 1 Biomarkers for coronavirus disease 2019 (COVID-19) , dengue, and co-infection by SARS-CoV-2 and dengue virus (DENV), along with their normal levels given for comparison

Platelet count (/μL) 150,000-450,000 23,000-31,000 <100,000 41,000-106,000 14, 54 White blood cell count (/μL) 3500-11,000 8000-12,000 <5000 1700-2380 absence or delay of treatments. Therefore, the public, the healthcare facilities, and the government must put up a united front to maintain high vigilance and take preventive measures against both DENV and SARS-CoV-2 as much as possible.

We apologize to all colleagues whose contributions were not discussed and cited owing to space constraints.

A novel coronavirus from patients with pneumonia in China

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG

Uso da saliva como um espécime alternativo para diagnóstico de COVID-19: uma revisão sistemática

Leukopenia: causes, treatment, and outlook. Medical News Today

Dengue infection

Dengue virus

Dengue and severe dengue. World Health Organization

Characteristics of patients Co-infected with severe acute respiratory syndrome coronavirus 2 and dengue virus

Experience of a tertiary hospital in Singapore with management of a dual outbreak of COVID-19 and dengue

Emergence of co-infection of COVID-19 and dengue: a serious public health threat

Dengue-COVID-19 coinfection: the first reported case in the Philippines

COVID-19 and dengue co-infection in a returning traveller

Co-infection of Dengue and COVID-19: A Case Report

A case study of dual infection of dengue and COVID-19: presenting as multiorgan dysfunction in an infant

Co-infection of malaria and dengue in pregnant women with SARS-CoV-2

Coronavirus disease 2019 and dengue: two case reports

Co-infection of SARS-CoV-2 and dengue virus: a clinical challenge

Coinfection, coepidemics of COVID-19, and dengue in dengue-endemic countries: a serious health concern

Dengue virus inoculation to human skin explants: an effective approach to assess in situ the early infection and the effects on cutaneous dendritic cells

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications

Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus/ Susan R. Weiss, Sonia Navas-martin

Human skin Langerhans cells are targets of dengue virus infection

Molecular insight into dengue virus pathogenesis and its implications for disease control

The COVID-19 pandemic: a global health crisis

ACE2: evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Circulating cytokines and chemokines associated with plasma leakage and hepatic dysfunction in Brazilian children with dengue fever

Endothelial dysfunction in dengue virus pathology

Preventing COVID-19-induced pneumonia with anticytokine therapy

Covid-19 and dengue: double punches for dengue-endemic countries in Asia

Generation of IgM anti-platelet autoantibody in dengue patients

Antiplatelet autoantibodies elicited by dengue virus non-structural protein 1 cause thrombocytopenia and mortality in mice

Anti-dengue virus nonstructural protein 1 antibodies recognize protein disulfide isomerase on platelets and inhibit platelet aggregation

Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Provides a Possible Pathway into the Central Nervous System; bioRxiv

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Ramanathan S. ADE and hyperinflammation in SARS-CoV2 infectioncomparison with dengue hemorrhagic fever and feline infectious peritonitis

HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption

Thrombosis and coagulopathy in COVID-19

The role of alveolar edema in COVID-19

Involvement of the central nervous system in patients with dengue virus infection

Covid-19 and dengue: double punches for dengue-endemic countries in Asia

Dengue virus infection of blood-brain barrier cells: consequences of severe disease

Acute disseminated encephalomyelitis associated with dengue infection: a case report with literature review

Neurologic complications in dengue virus infection: a prospective cohort study

Current neurological observations and complications of dengue virus infection

Central nervous system and muscle involvement in dengue patients: a study from a tertiary care center

The neurological manifestations of COVID-19: a review article

Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19

IL-10 and socs3 are predictive biomarkers of dengue hemorrhagic fever

Biomarkers of severe dengue disease-a review

Dengue and COVID-19, overlapping epidemics? An analysis from Colombia

The impact of COVID-19 disease on platelets and coagulation

Dengue fever, COVID-19 (SARS-CoV-2), and antibody-dependent enhancement (ADE): a perspective

Dengue after COVID-19 vaccination: possible and might be missed

Case report: extrapulmonary manifestations of COVID-19 and dengue coinfection

Clinical relevance and discriminatory value of elevated liver aminotransferase levels for dengue severity

Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis

Alanine aminotransferase-old biomarker and new concept: a review

Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19

C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study

Dengue fever and COVID-19 Co-infection at the emergency department of a tertiary care hospital in Jeddah, Saudi arabia

Case report: dengue and COVID-19 coinfection in Thailand

Co-infection of COVID-19 and dengue: a case report

Serological cross-reaction and co-infection of dengue and COVID-19 in Experience from Indonesia

COVID-19 with dengue shock syndrome in a child: coinfection or cross-reactivity?

Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects

Dengue diagnosis, advances and challenges

Early dengue diagnosis: role of rapid NS1 antigen, NS1 early ELISA, and PCR assay

Dengue serology in Indonesian COVID-19 patients: coinfection or serological overlap? IDCases

Differentiating Dengue from COVID-19: Comparison of Cases in Colombia

A combination of COVID-19 and dengue fever in Bangladesh: preparedness of Bangladesh

Case report: COVID-19 presenting as acute undifferentiated febrile illness-a tropical world threat

How to cite this article

SARS-CoV-2 and dengue virus co-infection: Epidemiology, pathogenesis, diagnosis, treatment, and management

The author declare no conflict of interest.

Yusha Araf conceived the study. Yusha Araf and Md. Golzar 

Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Noor-A-Afrin https://orcid.org/0000-0002-0041-8533Tanjim Ishraq Rahaman https://orcid.org/0000-0001-5225-5767Mohammad Jakir Hosen https://orcid.org/0000-0001-6444-0214Chunfu Zheng https://orcid.org/0000-0002-8797-1322Md. Golzar Hossain https://orcid.org/0000-0002-1487-5444